Avadel Pharmaceuticals PLC (NASDAQ:AVDL) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET
Company Participants
Austin Murtagh - Stern Investor Relations
Gregory Divis - CEO & Director
Richard Kim - Chief Commercial Officer
Jennifer Gudeman - SVP, Medical & Clinical Affairs
Thomas McHugh - SVP & CFO
Conference Call Participants
Ami Fadia - Needham & Company
Rudy Li - Leerink Partners
Matthew Kaplan - Ladenburg Thalmann & Co.
Francois Brisebois - Oppenheimer
Chase Knickerbocker - Craig-Hallum
David Amsellem - Piper Sandler & Co.
Operator
Greetings, and welcome to the Avadel Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions].
It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations. You may begin.
Austin Murtagh
Good morning, and thank you for joining us on our conference call to discuss Avadel's Third Quarter 2023 Earnings.
As a reminder, before we begin, the following presentation includes several matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties are described in Avadel's public filings under the Exchange Act included in the Form 10-K for the year ended December 31, 2022, which was filed on March 29, 2023, and subsequent SEC filings. Except as required by law, Aveda undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events or otherwise.
On the call today are Greg Divis, Chief Executive Officer; Richard Kim, Chief Commercial Officer; and Tom McHugh, Chief Financial Officer. Dr. Jennifer Goodman, Senior Vice President of Medical and Clinical Affairs, will join us for Q&A.
At this time, I'll turn the call over to Greg.
Gregory Divis
Thank you, Austin. Good morning, everyone, and thank you for joining us to review Avadel's third quarter 2023 results. We're excited to share the progress we have made with the launch of LUMRYZ. Following my opening remarks, Richard will provide an update on our launch progress. Tom will provide a review of our Q3 financial results, and we will conclude with a question-and-answer session.
The third quarter was transformational for Avadel as we fully transition to a commercial-stage company and are very pleased with the robust early demand generated and important emerging launch trends we are seeing. There is a tremendous opportunity for LUMRYZ and Avadel that lies ahead as we execute our launch. We believe the foundation we are building during these early months positions us incredibly well for continued success building on the momentum built during this first full quarter of launch.